1Y Close · As of Aug 26, 2026
OliX Pharmaceuticals operates in the Professional Services sector.
Legal name: OliX Pharmaceuticals, Inc.
Operating profit was -30.0 billion KRW and net income was -15.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 2.09 trillion KRW, with a P/B of 13.94.
These figures can be verified in the DART filing (receipt no. 20260318000903).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | — | -30.0B | -15.7B |
| 2024 | — | -30.9B | -40.7B |
| 2023 | — | -18.2B | -19.1B |
| 2022 | — | -22.4B | -21.9B |
| 2021 | — | -25.4B | -30.3B |
Recent Filings
투자판단관련주요경영사항 (Hansoh와의 공동연구 및 염기서열 이전)
Semi-Annual Report (2026.06)
Large Shareholding Report (Simplified)
Checks
3 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | 투자판단관련주요경영사항 (Hansoh와의 공동연구 및 염기서열 이전) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Large Shareholding Report (Simplified) |
| 2026-08-03 | Large Shareholding Report (Simplified) |
| 2026-07-30 | Extraordinary Meeting Result |